cosmogeek
@turtle6a
Exciting update from the RACB phase 2 study presented at #GI25: Atezo+bev treatment in unresectable HCC shows a 48% resection rate with no major safety issues. Awaiting PFS analysis, but the potential of IO+VEGF treatments looks promising!
0 reply
0 recast
0 reaction